Ozempic (GLP-1 Drugs)
Lawsuit
A rapidly growing number of lawsuits have been filed against the makers of Ozempic and similar drugs due to severe adverse reactions. If your loved one has died following treatment with this class of drugs, call our law firm immediately at 800-732-3216.
Legally Reviewed By: Rebecca Phillips
Mass Torts Director
- Page Last Updated:
- April 12, 2024
We are investigating numerous lawsuits against the makers of Ozempic and similar drugs prescribed to treat type 2 diabetes mellitus and obesity.
Ozempic is part of a class of drugs known as glucagon peptide-1, or GLP-1, receptor agonists. These drugs mimic the hormone GLP-1, which stimulates insulin production and controls gastric emptying after food is consumed. While Ozempic is the most well-known of these drugs, they are also marketed as Wegovy, Mounjaro, Victoza, Saxenda, and Rybelsus.
Drug manufacturers have a legal duty to provide safe products, utilize good manufacturing practices, and provide accurate, complete warning labels so doctors and patients can make informed decisions.
There are reports that some patients have died after receiving these drugs, which is the cause of our investigation. Contact us now for a free consultation if your loved one died from treatment with this class of drugs.
Ozempic Lawsuits Timeline
October 5, 2023
A study published in the Journal of the American Medical Association identified an increased risk of pancreatitis, bowel obstruction, and gastroparesis in patients who used GLP-1 receptor agonist drugs for weight loss.
September 30, 2023
As of this date, 25,358 adverse reactions have been reported.
September 22, 2023
The Semaglutide drug label was updated to include ileus as an adverse effect. Ileus is a condition that slows or paralyzes the movement of food in the stomach or intestines.
August 2, 2023
The first lawsuit alleging Ozempic and similar drugs cause gastroparesis was filed against Novo Nordisk and Eli Lilly in Louisiana by a patient who used Ozempic and Mounjaro. The lawsuit alleges that the defendants failed to provide adequate warnings and breached express warranties by marketing, distributing, and selling a harmful product.
January 16, 2023
An Australian woman reportedly died after taking Ozempic and Saxenda to slim down for her daughter’s wedding. The cause of death was listed as “acute gastrointestinal illness.”
March 28, 2022
The Ozempic drug label was updated to include the risk of gallbladder disease, which can necessitate the surgical removal of the gallbladder. Untreated infections can lead to gallbladder rupture, a life-threatening event.
February 5, 2018
Danish company Novo Nordisk started selling Ozempic in the United States.
By submitting this form, you agree to our terms & conditions. Please read full disclaimer here.
Why Are People Filing Ozempic Lawsuits?
Worldwide, there have been 1,497 reported deaths from GLP-1 receptor agonists as of the end of September 2023. In total, more than 25,000 people have suffered adverse events. The lawsuits against Novo Nordisk and Eli Lilly allege the pharmaceutical companies failed to provide adequate warnings and breached express warranties.
Failure to Warn
While the warning labels mention that the medication can delay gastric emptying and that nausea and vomiting are potential side effects, the plaintiffs assert they do not go far enough to warn about the risk of unreasonably dangerous consequences.
Who Qualifies To File an Ozempic Lawsuit?
If your loved one passed away after using semaglutide, tirzepatide, liraglutide, or other GLP-1 receptor agonists, you may be able to bring a lawsuit.
These drugs were marketed and sold under the following trade names:
- Wegovy
- Mounjaro
- Victoza
- Saxenda
- Rybelsus
Contact an Experienced Lawyer Today
If your loved one passed away after using Ozempic or similar drugs to treat diabetes or lose weight, – you deserve justice. Our experienced lawyers can help. Contact us today to learn more about how we can help and your legal options.
By submitting this form, you agree to our terms & conditions. Please read the full disclaimer
